评估败血症的免疫功能障碍
Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Mrunmayi Tilak
- 电话号码:612-624-9990
- 邮箱:mtilak@umn.edu
学习地点
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- 招聘中
- University of Minnesota
-
接触:
- Kristine Kancans
- 邮箱:kanca008@umn.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with and without sepsis in the ICU, compared to healthy volunteers
描述
ICU With Sepsis Inclusion Criteria:
-
Age ≥ 18
-
Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"
-
Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:
- Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
- An alteration in mental status
- Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
- An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)
ICU Without Sepsis Inclusion Criteria:
- Age ≥ 18
- Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis
Healthy Volunteer Inclusion Criteria
- Age greater or equal to 18
- ASA status 1, 2 or 3
- May include patients who are receiving dialysis in an outpatient setting
Exclusion Criteria (all groups):
- Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
- Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
- Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
- Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
- Patients with active or a history of acute or chronic lymphocytic leukemia
- Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
- Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
- Participation in another investigational interventional drug study within the past 4 weeks
- Current pregnancy
- Current incarceration
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
健康志愿者
|
No intervention is included in this study |
|
ICU败血症患者
|
No intervention is included in this study |
|
没有败血症的ICU患者
|
No intervention is included in this study |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
EliSpot - Day 1
大体时间:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
EliSpot - Day 4
大体时间:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
EliSpot - Day 7
大体时间:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
EliSpot - Day 14
大体时间:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
EliSpot - Day 21
大体时间:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
EliSpot - Day 28
大体时间:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Ex Vivo TNF Production - Day 1
大体时间:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Ex Vivo TNF Production - Day 4
大体时间:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Ex Vivo TNF Production - Day 7
大体时间:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Ex Vivo TNF Production - Day 14
大体时间:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Ex Vivo TNF Production - Day 21
大体时间:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Ex Vivo TNF Production - Day 28
大体时间:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
大体时间:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
大体时间:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
大体时间:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
大体时间:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
大体时间:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
大体时间:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Cytokines in Serum - Day 1
大体时间:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Cytokines in Serum - Day 4
大体时间:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Cytokines in Serum - Day 7
大体时间:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Cytokines in Serum - Day 14
大体时间:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Cytokines in Serum - Day 21
大体时间:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Cytokines in Serum - Day 28
大体时间:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Chemokines in Serum - Day 1
大体时间:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Chemokines in Serum - Day 4
大体时间:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Chemokines in Serum - Day 7
大体时间:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Chemokines in Serum - Day 14
大体时间:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Chemokines in Serum - Day 21
大体时间:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Chemokines in Serum - Day 28
大体时间:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Transcriptional Profiling - Day 1
大体时间:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Transcriptional Profiling - Day 4
大体时间:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Transcriptional Profiling - Day 7
大体时间:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Transcriptional Profiling - Day 14
大体时间:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Transcriptional Profiling - Day 21
大体时间:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Transcriptional Profiling - Day 28
大体时间:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
CBC - Day 1
大体时间:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
CBC - Day 4
大体时间:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
CBC - Day 7
大体时间:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
CBC - Day 14
大体时间:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
CBC - Day 21
大体时间:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
CBC - Day 28
大体时间:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
合作者和调查者
调查人员
- 首席研究员:Thomas Griffith, PhD、University of Minnesota
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.